ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XOMAO XOMA Royalty Corporation

25.26
-0.10 (-0.39%)
Last Updated: 18:47:44
Delayed by 15 minutes
Name Symbol Market Type
XOMA Royalty Corporation NASDAQ:XOMAO NASDAQ Preference Share
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.10 -0.39% 25.26 25.26 25.40 25.37 25.26 25.37 1,296 18:47:44

XOMA Royalty to Present at Upcoming Investor Conferences in September

04/09/2024 12:30pm

GlobeNewswire Inc.


XOMA Royalty (NASDAQ:XOMAO)
Historical Stock Chart


From Aug 2024 to Feb 2025

Click Here for more XOMA Royalty Charts.

XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:

  • H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY.  Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at 9:00 AM ET.  The presentation can be accessed at https://bit.ly/4coqH9K.
  • 2024 Cantor Global Healthcare Conference, which is being held September 17-19, 2024, in New York, NY. Mr. Hughes and Mr. Sitko will present a corporate overview on September 17, 2024, at 2:30 PM ET.  The presentation can be accessed at https://bit.ly/3yNkp5U.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

  
XOMA Investor ContactJuliane SnowdenXOMA Royalty+1 646-438-9754juliane.snowden@xoma.comXOMA Media ContactKathy VincentKV Consulting & Management+1 310-403-8951kathy@kathyvincent.com

1 Year XOMA Royalty Chart

1 Year XOMA Royalty Chart

1 Month XOMA Royalty Chart

1 Month XOMA Royalty Chart

Your Recent History

Delayed Upgrade Clock